Intellia Therapeutics, Inc. (NASDAQ:NTLA) Holdings Raised by Vanguard Group Inc.

Vanguard Group Inc. grew its position in shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA - Free Report) by 5.8% in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 10,190,053 shares of the company's stock after buying an additional 562,249 shares during the quarter. Vanguard Group Inc. owned 10.00% of Intellia Therapeutics worth $118,816,000 as of its most recent filing with the SEC.

Several other hedge funds also recently made changes to their positions in NTLA. Whipplewood Advisors LLC purchased a new position in Intellia Therapeutics during the fourth quarter worth about $40,000. Jones Financial Companies Lllp raised its position in shares of Intellia Therapeutics by 140.9% during the 4th quarter. Jones Financial Companies Lllp now owns 3,898 shares of the company's stock worth $45,000 after purchasing an additional 2,280 shares during the last quarter. Daiwa Securities Group Inc. raised its holdings in shares of Intellia Therapeutics by 80.6% in the fourth quarter. Daiwa Securities Group Inc. now owns 5,151 shares of the company's stock worth $60,000 after acquiring an additional 2,299 shares during the last quarter. KBC Group NV lifted its position in shares of Intellia Therapeutics by 62.4% in the fourth quarter. KBC Group NV now owns 6,093 shares of the company's stock valued at $71,000 after acquiring an additional 2,340 shares in the last quarter. Finally, AdvisorNet Financial Inc boosted its stake in shares of Intellia Therapeutics by 96.4% during the fourth quarter. AdvisorNet Financial Inc now owns 10,085 shares of the company's stock valued at $118,000 after acquiring an additional 4,950 shares during the last quarter. Institutional investors and hedge funds own 88.77% of the company's stock.

Intellia Therapeutics Stock Performance

Shares of Intellia Therapeutics stock traded up $0.64 during trading on Friday, hitting $7.41. 2,355,446 shares of the stock were exchanged, compared to its average volume of 2,322,979. Intellia Therapeutics, Inc. has a 12 month low of $5.90 and a 12 month high of $28.18. The stock's fifty day moving average is $9.15 and its 200 day moving average is $12.53. The stock has a market cap of $767.06 million, a PE ratio of -1.36 and a beta of 2.23.

Wall Street Analyst Weigh In

Several equities analysts recently issued reports on NTLA shares. BMO Capital Markets reduced their price objective on shares of Intellia Therapeutics from $70.00 to $50.00 and set an "outperform" rating on the stock in a research note on Friday, January 10th. Chardan Capital reduced their target price on shares of Intellia Therapeutics from $91.00 to $68.00 and set a "buy" rating on the stock in a report on Friday, February 28th. JPMorgan Chase & Co. restated a "neutral" rating and issued a $13.00 price target (down previously from $45.00) on shares of Intellia Therapeutics in a report on Friday, February 28th. Oppenheimer cut their price target on Intellia Therapeutics from $60.00 to $40.00 and set an "outperform" rating on the stock in a research note on Monday, January 13th. Finally, Wedbush restated a "neutral" rating and set a $10.00 price objective (down previously from $14.00) on shares of Intellia Therapeutics in a research note on Friday, January 10th. Two research analysts have rated the stock with a sell rating, six have given a hold rating, eleven have assigned a buy rating and one has assigned a strong buy rating to the company's stock. According to MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $37.56.

Intellia Therapeutics Profile

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.